ORGO Q2 2019 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$338M

Q2 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$65M

Gross Profit

$46M70.1% margin

Operating Income

-$7M-11.3% margin

Net Income

-$10M-14.9% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+13.7%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$13M

Stock-Based Comp.

$234,000

Balance Sheet

Total Assets

$168M

Total Liabilities

$145M

Stockholders' Equity

$23M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$65M	$0	—
Gross Profit	$46M	-$942,527	+4927.7%
Operating Income	-$7M	-$942,527	-676.5%
Net Income	-$10M	$356,988	-2802.9%

Revenue Segments

Advanced Wound care

$55M85%

Surgical and Sports Medicine

$10M15%